Bristol-Myers Squibb stock holds the mid-$60 range
Published on 09/01/2026 at 19:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock (ISIN US1078421011) closed at $66.47 on August 30, 2026, with a market capitalization of $135.98 billion. The shares were referenced near $66.58 the next day, while managements fiscal 2026 EPS guidance sits at $6.75 to $7.00 and consensus centers on $6.95.
Autoimmune CAR-T risk
The current market peg is the voluntary pause in autoimmune CAR-T enrollment, which keeps clinical safety in the spotlight for the Bristol-Myers Squibb story. According to an ad hoc news report, the company has paused enrollment in autoimmune studies of its experimental CAR-T program to review transient inflammatory events.
That same report puts the NYSE close at $66.47, the intraday range at $66.19 to $67.39, and the market cap at $135.98 billion as of August 30, 2026. The next-day reference near $66.58 leaves the shares only $0.11 above the prior close, a tight gap that signals a restrained trading band.
Guidance anchors valuation
Managements fiscal 2026 EPS guidance of $6.75 to $7.00 gives the stock a clear earnings frame, and the consensus figure of $6.95 sits $0.20 above the low end and $0.05 below the high end. That leaves Bristol-Myers Squibb trading against a mid-teens earnings multiple rather than a biotech-style growth premium.
For investors, the comparison matters: $66.47 in the market and $6.95 in consensus EPS define the present valuation more clearly than broad pharma sentiment. The result is a stock that is being measured on execution, not narrative.
Bristol-Myers Squibb shares and the 2026 outlook
A closer look at the 2026 earnings range, current quote level and pipeline risk.
Camzyos remains a growth asset
Camzyos remains one of the clearest product references in the portfolio, supporting the cardiovascular franchise alongside oncology and immunology. Recent conference coverage has kept attention on its longer-term data readout and on how durable uptake can add to 2026 revenue mix.
Stock level and setup
As of August 30, 2026, Bristol-Myers Squibb stock on the NYSE stood at $66.47, with market value at $135.98 billion. The combination of a $66.47 close, a $135.98 billion market cap and fiscal 2026 EPS guidance of $6.75 to $7.00 leaves the shares in a valuation band that reflects both cash generation and pipeline caution.
Bristol-Myers Squibb fact box
- Company: Bristol-Myers Squibb Co.
- ISIN: US1078421011
- Ticker: BMY
- Trading venue: NYSE
- Price (as of August 30, 2026, 3:59 p.m. ET): $66.47 USD
- Market capitalization: $135.98 billion (as of August 30, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: S and P 500
